Poslední aktualizace :
28/04/2024
Beta-blokátor   Labetalol hydrochloride  
Injekce
Perorální roztok
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy Pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Albetol Finsko
Biascor Argentina, Chile, Ekvádor, Peru
Blocamine Argentina
Cebalol Indie
Deltalol Kolumbie
Evabet Indie
Gravidol Indie
Labesol Indie
Labeta Indie
Labetalol Argentina, Kanada, USA
Labetalol chlorhidrato Chile, Ekvádor
Labil Indie
Trandate äpanÏlsko, Belgie, Chile, Dánsko, Finsko, Francie, Irsko, Island, Itálie, Japonsko, Kolumbie, Lucembursko, Malajsie, MaÔarsko, NÏmecko, Nizozemsko, Norsko, Nový Zéland, Polsko, Rakousko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, USA, Velká Británie
Zeverotens Chile
Odkazy   Injekce   Odkazy : Labetalol hydrochloride  
Typ Uveřejnění
62 Noviny Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
89 Noviny Zeisler J, Alagna C.
Incompatibility of labetalol hydrochloride and furosemide.
Am J Hosp Pharm 1993 ; 50: 2521-2522.
199 Noviny Hassan E, Leslie J, Martir-Herrero ML.
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 2143-2145.
241 Noviny Leader WG, Jones JM.
Incompatibility between ceftriaxone sodium and labetolol hydrochloride.
Am J Health-Syst Pharm 1996 ; 53: 2639.
295 Noviny Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
300 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
314 Noviny Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
315 Noviny Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
386 Noviny Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
398 Noviny Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
921 Noviny Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1194 Noviny Yuen PHC, Taddei CR, Wyka BE, Chaudry IA.
Compatibility and stability of labetolol hydrochloride in commonly used intravenous solutions.
Am J Hosp Pharm 1983 ; 40: 1007-1009.
1315 Noviny Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1380 Noviny Alam AS.
Identification of labetolol precipitate.
Am J Hosp Pharm 1984 ; 41: 74.
1490 Noviny Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508 Noviny Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 Noviny Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Noviny Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1712 Noviny Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Noviny Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Noviny Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1803 Noviny Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Noviny Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
2018 Noviny Veggeland T.
Visual compatibility of clonidine with selected drugs.
Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2090 Noviny Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 Noviny Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2262 Noviny Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Noviny Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012 Noviny Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3210 Noviny Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261.
3249 Noviny Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Noviny Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 Noviny Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3539 Laboratoř Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013
3540 Laboratoř Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3609 Laboratoř Labetalol (Trandate®) - Summary of Product Characteristics
Aspen Pharma 2013
3766 Noviny Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3823 Noviny Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
3824 Noviny Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Plakát Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakát Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakát So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Noviny Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3964 Noviny Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Noviny Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Noviny Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Noviny Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4433 Noviny Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4528 Noviny Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Noviny Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4642 Plakát Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner
Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia.
SEFH Congress (Virtual) October 2021 2021
4650 Laboratoř Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4742 Noviny Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales